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&&iuRg ad Taickung Taiwan and San Fmnciseo, California 
1990 aad 1993,76 asymptomatic nonrbeu- 
mskl to severe chronic aortic regurglCtioa 
were enrolled in a raado&ed, double-blind trinl muparIng 
endapril with bydmlaalne. All patients underwent serial nonIn= 
vasive studies. Seventy patients completed the 124nontb follow- 
UP 
. At 1 year, patients receiving carlspril bud a signllhit 
reductioa in lef9 ventricular enddlastolic and end-systolic volume 
iadexes (124 t IS vs. 108 t 17 mUmJ, p < 0.01; 50 t I2 vs. 40 f 
Patients with chronic aortic regurgitation often remain asymp 
tomatic for many ears despite severe valvular insufficiency 
{L-3). The aim of conservative management is o prevent 
decompenaaion of the lef! ventricle for as long as possible (4). 
The strategy ofreducing the alterload on the left ventricle has 
been applied successfully to patients with chronic aortic regur- 
gitation (4). However, the ability of pharmacologic treatment 
to prevent or delay myocardia! dysfunction remains unproved 
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ww by the American College of Cardiology 
nbly influence the naturai bistury of chronic 
(5,6). A challenging hypothesis is that !he early administration 
of a vasodilator d ug during the long-standing asymptomatic 
phase of volume overload without myocardial deterioration 
might be able to reduce regurgitant volume and left ventricular 
afterload and improve l ft ventricular function in aortic regur- 
gitation (7-9), but little information is available on the effects 
of tong-term angiotensin-converting enzyme inhibitor therapy. 
Controversy exists about the efficacy oflong-term treatment 
with hydralaxine. In a randomized 6-month trial of hydral- 
azine, Kleaveland eta!. (1) found nu significant changes in 
treadmill exercise duration or peak oxygen consumption a d 
left ventricular dimension, volume and hypertrophy. More 
recently, Greenberg et a!. (3) showed that 24 months of 
hydralazine therapy reduced left ventricular end-diastolic vol- 
ume and suggested that such therapy may have a beneficial 
effect on the natural history of the disease despite a high 
incidence (76%) of side effects. These hvo trials uggest a very 
limited role of hydralazine therapy in asymptomatic patients 
with moderate osevere chronic aortic regurgitation. 
An angiotensin-converting enzyme inhibitor generally re- 
duces the production ofthe potent vasoconstrictor angiotensin 
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coronary vasoco~s~rict~ mias (11). Thus, the 
benefits of inbibi~io~ probably extend beyond the classic 
genie-a~gio~eosi~ sy tem to include the heart di- 
ause the renin-angiotensin system ay be activated 
itation (4), this combined arteriolar nd 
e potem~ia~ for benefit in t 
reg~rgi~at~~~rl. To explore tl
verting enzyme inhibiror and its ~1~~0~1d~~g 
ndomized dou~~e-~)~il~~ trial to test he 
hypot~lesis that ~oog-terl~~ vasodilato~ therapy with enalapril 
not only reduces left ventricular overload, volume and mass 
indexes but also inhibits the rcnil~-al~giotc~s~~l system in con- 
trast to l~ydrala2i~le the~aQy in asynlpt~l~atic 
chronic aortic regurgitation. 
From January 1, 1990 to September 31, 1993,96 nonrheu- 
matic patients with chronic asymptomatic ortic regurgitation 
were enrolled and randomized in this study. All patients were 
veterans or veteran dependents. The study protocol was ap 
proved by the Ethics Committee ofVeterans General Hospi- 
tal, and written informed consent was obtained in all cases. 
The severity ofchronic aortic regurgitation (ranging from 29 
to 4t) was quantified by mapping the regurgitant je into the 
left ventricle by Doppler color flow imaging. Aortic regurgita- 
tion was considered to be present by Doppler color Row 
examination when an abnormal diastolic flow originating from 
the aortic valve was visualized in the left ventricle. The severity 
of aortic regurgitation was graded using the Perry et al. (12) 
method as follows: the thickness of the regurgitant stream at its 
origin in the high left ventricular outflow tract, measured in 
both one dimension (jet height from the parasternal long-axis 
view) and two dimensions ( hort-axis area in the high left 
ventricular outflow tract). This method has been applied 
accurately to predict he severity of aortic regurgitation as
determined byangiographic grading (12). Only asymptomatic 
patients were included in this trial. Other exclusion criteria 
were atrial fibrillation, pulse pressure 40 mm Hg, history of 
recent development or worsening of aortic regurgitation within 
the preceding 6 months, history of coronary artery disease, 
significant Fixed aortic stenosis and regurgitation (mean pres- 
sure gradieut ~50 mm Hg), evidence ofadditional valvular or 
congenital heart disease by echocardiographic and color 
Doppler evaluations and history of previous cardiac inotropic 
therapy (e.g., digitalis or dopamine). Admission to the study 
required a high quality echocardiographic left ventricular 
study. No patients underwent cardiac catheterization. 
. Clinical Characteristics of Patients With Asymptomatic 
C~UXI~C A&c Regu~git~tj~~ Treated With En&+\ 
and ~y~ra~~z~ne 
Age Cvr) 
Gender (M/F) 
Duration of AR (yr)* 
Mean severity of AR 
Mild/moderate/severe 
With SBP ~180 mm Hg 
Etiology 
Thickened/degenerative lea 
Dilated aortic root 
Uncertain 
Echo data 
LVEDVi (ml/ill") 
LVESVl (ml/m?) 
E[: (‘;‘,) 
MWS (kdyns/cm’) 
Mass index (g/m’) 
Dwg rcgimco 
Withdrdwai 
Vasodilator alone 
Mean dose (mg/day) 
Additive diuretic drug? 
Enalapril Hydralaiine 
(n = 38) (n = 38) 
66 r 7 65 t- 6 
3414 3612 
623 623 
3 3 
11/16/lI 11/16/11 
18 18 
25 26 
10 IO 
3 2 
125 -t 1s 125 r 15 
51 + I? soz 12 
60 +_ 5 6(1 +- 5 
378 ? 3s 376 + 37 
131 + I5 131 r 16 
38 38 
3 3 
21 16 
31 177 
8 19 
“Established by historical information from the patient or from physician 
records. tp = NS tar all indexes at study entry, except for added diuretic drug (p < 
0.05). Data presented are mean vahe 2 SD or number of patients. AR = aortic 
regurgitation; Echo = echocardiographic; EF = ejection fraction; F = female; 
LVEDVI (LVESVI) = left ventricular end.diastolic (end-systolic) volume index; 
M = male; MWS = mean wall stress; SBP = systolic blood pressure. 
y protocol. The initial assessments of all patients in- 
cluded a complete history and physical examination, complete 
blood count, blood biochemistry screen and urinalysis, IWead 
electrocardiography, neurohumoral assays inthe supine posi- 
tion (fasting state), treadmill exercise t sting (Bruce protocol) 
and detailed echocardiograpbic study. 
On completion of baseline studies, treatment was begun 
with either enalapril or hydralazine onthe basis of predeter- 
mined age-matched, severity-oriented randomization rder. 
An assistant took charge of the drug dispatch. Neither the 
study physician nor the patients were aware of which treatment 
was given. The characteristics of all patients who wer,: enrolled 
and randomized in the trial are listed in Table 1. Echocardio- 
graphic evaluations, treadmill exercise t sts and neurobumoral 
assays were repeated at6 and 12 months after andomization. 
aerodynamic m~as~re~~~ts and clinical assessment. 
Physicians or trained registered nurses used standard sphyg- 
momanometers with appropriately sized cuffs to determine 
blood pressure and pulse pressure. The patients were seated 
with an arm supported atthe level of the heart after 10 min 4 
rest. Disappearance of the Korotkoff sounds defined the 
diastolic blood pressure. Heart rate was calculated bycounting 
the pulse for 1 min. The mean of two readings taken 1 to 3 ;n 
apart was used as the blood pressure atthat clinic visit. PUISC 
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pressure was derived from the difference between systolic and 
diastolic blood pressures. 
A checklist as used to inquire about the patients’ side 
effects. The patients were encouraged to describe their symp- 
toms at each visit. All withdrawals or exclusions from the study 
protocol were evaluated in blinded manner by the study 
chairman and classified as administrative or medical. All 
clinical results are reported according to an intention-to-treat 
analysis. 
Neurobumeral determinations. All patients were placed 
on a regular diet containing 5 g of sodium daily, and all 
patients had free access to water. All vasodilator and diuretic 
drugs were withdrawn in the hospital 3 to 5 days before the 
haselinc hormonal studies. No patients took a digitalis prcpa- 
ration. Rlood was drawn on the morning (8 to 8:30 AM) of the 
fifth day, after the patients had been supine and fasting 
overnight, The samples were collected and spun immcdiatcly, 
and the plasma was separated and frcyzcn until the time of the 
assay, Plasma renin activity, aldosterone and antidiuretic hor- 
mone were detcrmincd by radioimmunoassay (13-15). After 
discharge, all patients had a regular diet with 4 to 6 g sodium 
(average 5 g daily) during long-term follow-up. All patients 
continued optimal vasodilator therapy with or without diuretic 
drugs 2 months after hemodynamic end points wcrc achieved. 
Repeated neurohumoral assays were performed at the sched- 
uled time in the same way during either enalapril or hydral- 
azine therapy. 
Echocardiographic examinations were coded and read by two 
independent observers who did not know the patient’s identity 
or the order of the studies. A discrepancy 810 ml for left 
ventricular volume and 210 g for left ventricular mass index 
required repeated anar~~: q..c the echocardiographic tracing by 
a third observer. Agreement was achieved by consensus. 
Interobserver and intraobsetver variability for left ventricular 
area (r = 0.97 and r = 0.96, respectively) and for left 
ventricular length (r = 0.96 and r = 0.95, respectively) was 
acceptable. All echocardiographic measurements were made 
according to the recommendations of the American Society of 
~ch~~~~rdi[~gra~hy (5,16). Left ventricular mean wall stress 
(MWS) was ntei~surd 1,~ corn~~i~~in~ peak systolic arterial 
pressure measurements (SAP) (cuff method) of left ventricular 
radius and posterior wall thickness as follows (5,17): 
Drug administration. A giotensin converting-enzyme in- 
hibition was started with enalapril, 5 mg twice daily for 2 
weeks. The dosage was increased to 10 mg twice daily for the 
next 2 weeks. Finally, enalapril was increased to 20 mg twice 
daily for another 2 weeks. If this was tolerated without any 
adverse reactions, the dosage was maintained at the maximal 
level as long as possihlc. Diuretic drugs were added if systolic 
blood pressure was > 160 mm Hg and pulse pressure reduction 
was below the predetermined 15% level of initial pressure 
gradient or if pitting edema of the lower legs developed. 
C%nventional vasodilator therapy started with 25 mg of hydral- 
azine two times daily for 2 weeks. The dosage was increased to 
50 mg of hydralazinc two times daily for the next 2 weeks. The 
principles of drug administration were applied in the same way 
during tither enalapril or hydralazine therapy. 
where CF = conversion factor (CF = I kdyne/cm’ mm Hg), 
and Rm and Thm = averages of end-diastolic and end-systolic 
values of the left ventricular radius (R) and wall thickness (Th) 
(cm). These measurcmcnts were on -mode tracings derived 
from two-dimensional visualization of the left vcntriclc in the 
parasternal short-axis view. Although peak systolic pressurc 
was used instead of end-systolic pressure for calculation, mean 
wall stress represents a good noninvasive indicator of peak left 
ventricular end-systolic wall stress as shown by correlations 
with angiographic data (17). Left ventricular endocardial and 
epicardial echocardiograms in apical four-chamber and 
parastcrnal short-axis vietvs for a minimum of five cardiac 
cycles were digitized at end-diastolc (R wave peak) and 
end-systole (time of the smallest cavity area) by two indepen- 
dent observers. Left ventricular volumes were calculated by an 
ellipsoid biplane area-length model (5,18). and ejection frac- 
tion (5) was derived as: (EDV - ESV)/EDV, where EDV and 
ESV = left ventricular end-diastolic and end-systolic volumes, 
respectively. Left ‘ventricular myocardial mass was calculated 
by multiplying the myocardial volume by the specific weight of 
cardiac muscle (1.05 @ml) ($19). All values were expressed as 
an index (m’) by dividing by body surface area. 
Medication dose was not increased if there were signiticant 
side effects or if hemodynamic end points were met: systolic 
blood pressure ~140 mm Hg, diastolic blood pressure 
190 mm Hg and pulse pressure reduction equal to greater 
than the initial 20% of pressure gradient. In all, the mainte- 
nance dosage depended on the physician’s clinical assessment, 
hemodynamic end points and adverse reactions of the assigned 
tn%tment. Thus, the general guideline of therapy was that the 
maximal vasodilator was maintained if possible without signif- 
icant untoward reactions. 
Statistical nalysis. Results are reported as mean values +- 
SD. The Student t test and chi-square test were used for the 
baseline comparisons of the two groups for the data in Table 1. 
Analysis of variance techniques were used to analyze the data 
presented in Tables 2 to 4. The post-hoc test used was the 
Scheffe method. Cienerai linear models were used to analyze 
the independent contributions of clinical variables and study 
drugs on left ventricular end-diastolic and end-systolic vol- 
umes, left ventricular mass and left ventricular ejection frac- 
tion. A p value C 0.0s was considered statistically significant. 
Ebffd&raphic analysis. Two-dimensional echocardio- 
grams were coded with a commercially available lnterspect 700 
Baseline comparisons and ~~~~~w-~~. From 1990 to 1993, 
mechanical array ultrasound system with a ~&MHZ trans- 
90 patients were initially included. To achieve a homogeneous 
ducer. Measurements were performed at the end of the trial. 
population, 14 patients with rheumatic heart disease were 
excluded. Seventy-six patients with nonrheumatic aortic regur- 
I’
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‘:‘ahle & Comparison of khocardiographic Analysis in Patients Treated With Enalapril and Hydralazine 
Ena!apcil Hydraiazine p Value (enalapril vs. hydralazine) 
Baseline 6mo 12 mo Baseline 6mo 12 mo Baseline 6mo I2 mo 
LVMW!3 (kdyneh’) 379 + 35 313 2 L7* 308 rt 30* 376 2 39 3u8 2: 20* 306 2 21* NS NS NS 
LVEDVI (ml/m’) 124 2 IS 108 2 17’ 108 2 16: 125 ? 16 123” 17 121 + 17 NS <: 0.01 < 0.01 
LVESVI (mum*) so+ 12 41 2 13’ 40% 14’ 50 + 15 48 2 14 472 14 NS < 0.05 -=. 0.05 
EF (W 6025 63 2 6 6426 6025 62 2 6 61 2 7 NS NS NS 
LVMI (g/m”) 13i 2 16 114 If: 18’ 113 r 19* 131 + 16 127 % 16 127 + 18 NS < 0.01 < 0.01 
*p c 0.01,6- or 12month values compared with baseline values f3r each drug. Data presenled are mean value 2 SD. LVMI = lett ventricular mass index; 
LV~WS = left ventricular mean wall slrw; other abbreviations as in Table 1. 
p < O,Ol). A statistically significant reduction in left ventricuhr 
en&diastolic volume index was observed between these two 
groups after 6 and 12 months of follow-up evaluations (p < 
0.01) (Fig, 2, top), Left ventricular end-systolic volume index 
also showed similar findings (for hydralazine, baseline 50 2 15, 
6 months 4g 2 14 and 12 months 47 L 14 ml/m”, respectively, 
p = NS; for enalapril, baseline 50 2 12,6 months 41 z!z 13 and 
12 months 40 c 14 ml/m’, respectively, p < 0.01). The latter 
s at 6 and 12 months were still significant when com- 
with both baseline and hydralaxine-treated group values 
< 0.05) (Fig. 2, middle). A mild increase in ejection fraction 
was detectable in both the enalapril- and hydralazine-treated 
patients (p = NS after 6- and 1Zmonth follow-up) (Fig. 2, 
bottom). 
Statistical analysis. General linear models were used to 
analyze the change in left ventricular end-diastolic volume 
index from baseline to 6 months. The statistically significant 
independent predictor variables were age and treatment drug 
(Table 5). Age was positively correlated with the change in left 
ventricular end-diastolic volume index. Enalapril was associ- 
ated with greater changes in left ventricular end-diastolic 
volume index than was hydralazine. The multiple rz value for 
the analysis was 72% (p < 0.01). Similarly, the predictor 
variables for the change in left ventricular end-systolic volume 
index left ventricular mass were the same as those for the 
in left ventricular end-diastolic volume index. 
Discussion 
nd. Chronic aortic regurgitation causes increases 
and mass and in some cases a 
decrease in left ~~~~~~~c~~ar function (l-5). Changes in left 
ventricular loaditng condition with increased left ventricular 
wall stress, decreased myocardial efficiency and chronic sec- 
ondary hypertropk processes can lead to myocellular contrac- 
(5,9,20-22). Furthermore, the chronic 
d left ventricle can develop irreversible 
nal changes even though the patient 
Because at present there is no evidence 
replacemenl is indicated in asymptom- 
normal left ventricular function (5,23-26), 
the value of vasdilator drugs in these patients is not clear. 
Afterload reduction by arteriolar vasodilator agents has been 
dccumented to decrease left ventricular end-systolic and en 
diastolic volume indexes in patients with significant aortic 
regurgitation compared with placebo (3,5). Because the renin- 
angiotensin system is usually stimulated in aortic regllrgitat~on 
Figure 1. Changes in mean wall stress (MWS) and left ventricular 
mass index (LVMI) over time for the two study groups. Top, Mean wall 
stress decreased significantly in the enalapril- and hydralazine-treated 
groups (p = NS hetween the two groups). Bottom, Left ventricular 
mass index did not change in patients with hydralazine therapy but 
decreased significantly in the enalapril-treated patients. **p < 0.01. 
I _..  ^ .._ - 
0 6Monrh~ 1ZMonthr 
JACC Vol. 24, No. 4 
October 1999:1046-53 
LIN ET AL. 
ENAUJ’RIL FOR CHRONIC AORTIC REGURGITATION B051 
s’: 
iii 
i 
501. 
0 
Figure 2. Changes in left ventricular end-diastolic (LVEDVI) and 
end-systolic (LVESVI) volume indexes and ejection fraction over 
time for the two study groups. Left ventricular end-diastolic and 
end-systolic (middte) volume indexes did not change significantly in 
the hydralazine-treated group but decreased significantly in the 
enalapril-treated group. Ejection fraction (bottom) increased slightly 
in both the enalapril- and hydralazine-treated groups (p = NS). *p -=c 
0.05. **p < 0.01. 
(4$, it appears that angiotensin-converting enzyme inhibitor 
therapy may be beneficial. 
Previous and recent studies on vasodilatos therapy, Un- 
loading agents may increase the myocardial efficiency and limit 
the stimulus to hypertrophy b decreasing left ventricular wall 
stress (5,6). In a randomized 6-month trial of hydralazine in 
asymptomatic patients with moderate osevere aortic regurgi- 
tation, Kleaveland etal. (1) found no significant changes in
treadmill exercise duration, peak oxygen consumption, left 
ventricular dimensions or hypertrophy. More recently, Green- 
berg et al. (3) showed that 24 months of treatment with 
hydralazine r duced the volume overload in chronic dortic 
regurgitation a d suggested that such therapy may have a 
beneficial effect on the natural history of the disease. Thus, 
hydralazine was the first drug that was demonstrated o reduce 
. Intensity Changes in Left Ventricular End-Diasloiic 
Vohne Index by ~~lt~var~ate Analysis 
B Value 
Variable (SE)’ t Value 
Intercept -16.82 (21.8) -0.8 
Class 0.65 (1.7) -0.4 
Age 0.66 (0.3) 2.2t 
Drug -14.25(1.3) -ll.l$ 
Gender 1.62 (2.4) 0.7 
PP 0.01 (0.1) 0.0 
Diuretic drug 0.70 (1.9) 0.4 
LV mass 0.14 (0.2) 0.8 
*Regression coefficient (standard deviation). tp < 0.05. Sp < 0.01. F = 22.9 
(p < 0.01); r’ = 72.1%. LV = left ventricular; PP = pulse pressure. 
left ventricular volume when given long term. Unfortuna(ely, 
the latter study does not provide data with regard to changes in
left ventricular mass during hydralazine therapy. In 1Y90 
Scognamiglio et al. (5) presented the results of a IZmonth, 
randomized, ouble-blind, placebo-controlled trial of nifedi- 
ine in 72 asymptomatic patients with severe aortic segurgita- 
(ion. There was a significant reduction i 1 echocardiographi- 
tally determined left ventricular end-diastolic volume and 
mass indexes and an increase inejection fraction (5). These 
two trials uggest a potentiai value of long-term treatment with 
an arteriolar dilator (nifedipine and hydralazine) in asymptom- 
atic patients with chronic aortic regurgitation (3,5). 
Reske et al. (4) first demonstrated that an angiotensin- 
converting enzyme inhibitor (captcpril) mediated a ecrease in 
regurgitant volume and suppressed the renin-angiotensin sys-
tem in patients with aortic regurgitation. It is well known that 
angiotensin-converting enzyme inhibitor reduces the produc- 
tion of the potent vasoconstrictor angiotensin II as well as 
causing arteriolar nd venous capacitance dilation (4). It also 
reduces production ofaldosterone and antidiuretic hormone 
(4). Thus, this balanced vasodilator has several desirable 
properties compared with those of a conventional arteriolar 
dilator such as hydralazine. 
Furthermore, there has been a recent evolution in the 
understanding of the actions of angiotensin II, which is viewed 
mainly as a vasoconstrictor with secondary effects o induce cell 
hypertrophy (10). According to molecular theory, angiotensin 
II may have been derived from a primitive growth factor so 
that it could utilize calcium fluxes to mediate its effects on the 
increases of smooth muscle tone and myocardial contractility 
(10). Thus, angiotensin II may be an important factor in 
inducI:lg cardiac mass increase. Moreover, the degree of 
cardiac hypertrophy is load dependent. Among other factors, 
the renin-a\,giotensin system ay play a role in the regulation 
of cardiac myocyte growth (11). All of these ffects should be 
of value in the long-term management of chronic aortic 
regurgitation. Because there are theoretic benefits in using an 
angiotensin-converting enzyme inhibitor over arteriolar vaso- 
dilators, it is useful to compare cnalapril with a known 
arteriolar dilator (hydralazine) in asymptomatic patients with 
significant aortic regurgitation. 
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‘~&e vent stady. Enalapril, an angiotensin-converting 
ewe inhibitor, may have advantages for afterload reduction 
in aortic regurgitation compared with hydralazine. Let? ven- 
tricular ventricular dilation and hypertrophy develop in re- 
sponse to chronic regurgitant flow, and this phenomenon may 
reged the severity and duration of aortic regurgitation (27). 
Moreover, left ventricular dilation and mass are important 
predictors of the need for aortic valve replacement and, when 
exeessjvely large, can limit the reversibility of left ventricular 
dysfunction after operation (24,2!l). Thus, it is rational that 
early treatment producing sustained reductions in left ventric- 
ular end-diastolic volume and mass might retard the appear- 
ance of irreversible structural myocardial lesions and delay 
aortic valve replacements (5). The results of this trial in 
asymptomatic patients with chronic aortic regurgitation clearly 
demonstrate that long-term enalapril unloading therapy favor- 
ably affects left ventricular dimensions, hypertrophy, volume 
and function. Enalapril significantly suppresses the rcnin- 
angiotensin system despite diuretic drugs in patients with 
chronic aortic regurgitation, as shown by an increase in the 
concentration of plasma renin activity and a decrease in the 
concentration of plasma ldosterone. In contrast, hydrahtxine 
therapy activates the renin-angiotensin system. Added diuretic 
drugs may further vate activation f the renin-angiotensin 
system. Thus, the useful findings in this study arise from 
our direct comparison f enalapril and hydralaxine regimens 
on left ventricular performance and the renin-angiotensin 
system. 
Many investigators have demonstrated that convertirrg- 
enzyme inhibitors regress cardiac hypertrophy and reduce 
tissue angiotensin II, not only in hypertensive animals (2831) 
but in humans as well (31-33). On the basis of clinical and 
experimental observations, we suggest that the beneficial ef- 
fects of enalapril are attributed to balanced vasodilatory 
activity and renin-angiotensin system inhibition. 
Reflex tachycardia, which is often seen after treatment with 
arteriolar dilators such as hydnlazine was not observed after 
en&pril therapy. Although we did not check angiotensin I and 
II lev& we ulate that his finding may be explained by a 
reduction i the angiotensin II-mediated component of sym 
pathetic tone (4). In addition, both left ventricular snd- 
diastolic and end-systolic volume indexes and left ventricular 
mass index were significantly reduced in the patients treated 
with enalapril, and over time the serial changes were signifi- 
Ca@ different from those in hydralaxine-treated patients. 
Although both regimens could significantly reduce left venttic- 
ular wall stress, enalapril therapy prevented left ventricular 
dilation and mass progression. 
It is not clear why hydralazine did not significantly decrease 
left ~nttieuhtr end-systolic and enddiastolic volumes in this 
study as it did in the Greenberg et al. study (3). Possible 
explanations are that he mean duration and treatment were 
longer in the Greenberg et al. study and that he mean dose of 
hydralaxine was higher. Volume index was determined by 
radionuclide angiography in the Greenberg et al. study and by 
two-dimensional echocardiography in the present study. 
The beneficial effects of enatapril could be a result of its 
complex pharmacologic activities, which include several com- 
ponents: 1) balanced venous and arteriolar vasodilating action; 
2) suppression f the activated renin-angiotensin system; an 
3) reduction of ventricular wall stress. These actions coul 
reduce the stimulus to myocardial hypertrophy (34). 
et al. (35) found that sympathetic a tivity and, specifically, 
transmyocardial norepinephrine release are reduced uring 
exercise by enalapril, and this effect has been cited as a 
potential antiischemic and antianginal mechanism for this 
agent (34,359. These actions could explain the regression in left 
ventricular volumes a by enalapril and t 
absence ofsiglti~~~nt alazinc. The sustaine 
reduction in left veu ss, detectable in bot 
groups, may have been an im~rtant factor in left ventricular 
ean wall stress is a factor that strongly in 
ventricular function in patients with aortic regurgitation 
(S&37), and a sustained unloading action may be important 
in delaying structural damage of the myocardtum (5). In this 
regard, both drugs may have a similar beneficial potential to 
influence the natural history of aortic regurgitation. Because 
hydralazine therapy activates the renin-angiotensin system to a 
greater degree than enalapril, this action may attenuate its 
unloading effect in the long-term management of chronic 
aortic regurgitation. By multivariate analysis, enalapril therapy 
clearly showed significant decreases in left ventricular cnd- 
diastolic and end-systolic volume indexes as well as left ven- 
tricular mass in contrast to hydralazine therapy. 
Stu it~~o~s. There are several important limitations 
to this study. The most important isthat we do not know for 
certain that these patients would not benefit from a higher 
dose (30G or 400 mg daily) of hydralazinc therapy because of
the initial design restrictions. Although itis possible that some 
patients dropped out as a result of intolerable side effects or 
because of cultural factors or racial dilizences, it is also 
possible that a higher dosage of hydralaztue might have 
resulted inregression f left ventricular mass and reduction of
left ventricular volumes equal to that produced by enalapril 
therapy. 
The second limitation isthat we cannot be sure what he 
clinical characteristics were tn asymptomatic patients with 
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activation f the renin-angiotensin system. Inthis study, we did 
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was not included, and an individualized optimal maintenance 
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ionuclide a~giOg~a~l~y was not obtained 
eforc, early detection of left ventricular 
nonrheumatic group of patients with chronic aortic regurgitation 
cannot necessarily be generalized to a rheumatic group of pa- 
tients without further validation. 
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